Recursion Pharmaceuticals (RXRX) Q2 2026 earnings summary

Executive summary

• Achieved a major inflection point with five clinical-stage programs, including REC-4881 and REC-7735, and significant partnership progress with Sanofi and Roche Genentech, generating over $500 million in inflows.

• Advanced first-in-class neuroscience target with Genentech into early discovery, validating the AI-native platform for novel drug target identification.

• Internal pipeline advanced with REC-4881 showing 43% median polyp burden reduction in phase II and REC-7735 IND clearance, with multiple oncology and rare disease programs progressing.

• Leadership team strengthened with appointments of Chief AI Officer and Head/SVP of Drug Design, enhancing AI and drug discovery expertise.

• AI-native engine leverages proprietary multimodal data, lab-in-the-loop experimentation, and continuous learning to accelerate drug discovery.

Financial highlights

• Lowered 2026 full-year cash operating expense guidance to under $375 million, a nearly 40% reduction from 2024 pro forma expenses.

• Cash, cash equivalents, and restricted cash totaled $556.8 million as of June 30, 2026, providing an operating runway through early 2028.

• Revenue for Q2 2026 was $7.7 million, down 60% year-over-year, primarily from collaborations.

• Net loss for H1 2026 was $248.5 million, a 34% improvement from the prior year, reflecting reduced R&D and G&A expenses.

• Partnerships have delivered over $500 million in cash inflows, with all collaborations structured to be break-even or profitable.

Outlook and guidance

• Additional phase II data for REC-4881 and regulatory updates expected before year-end, with further FDA engagement ongoing.

• REC-7735 Phase 1/2 trial initiation planned for 2H26, with early safety and PK data expected in 1H28.

• Multiple internal and partner-driven milestones anticipated through 2027, including further candidate nominations from Sanofi and Roche Genentech.

• Cash runway expected to extend into early 2028 based on current operating plans and no additional financing.